Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...
A University of Colorado professor won the 2024 Alton Ochsner Award for his work on disease risk factors for idiopathic ...
A research group from Ningbo Institute of Materials Technology and Engineering (NIMTE) of the Chinese Academy of Sciences ...
Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of ...
GlobalData on MSN7d
Boehringer seeks approval for lung fibrosis drug following Phase III winThe Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.
The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...
The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...
Medical Xpress on MSN14h
Fibrosis lacks treatments and methods of reversal: Study pinpoints a promising target for drug therapyMedical science has long been on the hunt for a deeper understanding of the devastating scarring of the body's organs known ...
The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute ...
After his brother's diagnosis, columnist Sam Kirton has new questions about the nature of familial idiopathic pulmonary fibrosis.
Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...
Among patients with PPF, those treated with 60 mg of admilparant showed significant decreases in periostin, ferritin, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback